Cite
HARVARD Citation
Dummer, R. et al. (2018). Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology. 19 (10), pp. 1315-1327. [Online].